Fidelity Investments’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.5K | Buy |
1,752
+12
| +0.7% | +$141 | ﹤0.01% | 4615 |
|
|
2025
Q4 | $25.9K | Sell |
1,740
-142
| -8% | -$2.48K | ﹤0.01% | 4367 |
|
|
2025
Q3 | $36.2K | Sell |
1,882
-266,822
| -99% | -$4.26M | ﹤0.01% | 4108 |
|
|
2025
Q2 | $2.99M | Sell |
268,704
-825,768
| -75% | -$7.27M | ﹤0.01% | 2346 |
|
|
2025
Q1 | $15.3M | Buy |
1,094,472
+3,887
| +0.4% | +$60.9K | ﹤0.01% | 1770 |
|
|
2024
Q4 | $18.1M | Sell |
1,090,585
-52,278
| -5% | -$850K | ﹤0.01% | 1761 |
|
|
2024
Q3 | $21.6M | Buy |
1,142,863
+7,005
| +0.6% | +$142K | ﹤0.01% | 1683 |
|
|
2024
Q2 | $16.4M | Buy |
1,135,858
+3,287
| +0.3% | +$54.8K | ﹤0.01% | 1713 |
|
|
2024
Q1 | $17.5M | Buy |
1,132,571
+163,142
| +17% | +$3.52M | ﹤0.01% | 1703 |
|
|
2023
Q4 | $27.1M | Buy |
969,429
+7,894
| +0.8% | +$207K | ﹤0.01% | 1510 |
|
|
2023
Q3 | $45.8M | Buy |
961,535
+2,275
| +0.2% | +$174K | ﹤0.01% | 1273 |
|
|
2023
Q2 | $91.9M | Buy |
959,260
+13,687
| +1% | +$1.49M | 0.01% | 1031 |
|
|
2023
Q1 | $107M | Buy |
945,573
+11,135
| +1% | +$1.2M | 0.01% | 953 |
|
|
2022
Q4 | $105M | Buy |
934,438
+3,901
| +0.4% | +$523K | 0.01% | 953 |
|
|
2022
Q3 | $119M | Buy |
930,537
+476
| +0.1% | +$48.8K | 0.01% | 894 |
|
|
2022
Q2 | $63.8M | Buy |
930,061
+236,168
| +34% | +$20.3M | 0.01% | 1155 |
|
|
2022
Q1 | $98.8M | Buy |
693,893
+5,039
| +0.7% | +$775K | 0.01% | 1066 |
|
|
2021
Q4 | $115M | Buy |
688,854
+965
| +0.1% | +$153K | 0.01% | 1042 |
|
|
2021
Q3 | $95.8M | Buy |
687,889
+41,935
| +6% | +$8.21M | 0.01% | 1123 |
|
|
2021
Q2 | $308M | Buy |
645,954
+31,920
| +5% | +$13.5M | 0.02% | 643 |
|
|
2021
Q1 | $253M | Buy |
614,034
+47,205
| +8% | +$21.7M | 0.02% | 683 |
|
|
2020
Q4 | $278M | Buy |
566,829
+30,959
| +6% | +$18.1M | 0.02% | 613 |
|
|
2020
Q3 | $303M | Buy |
535,870
+248,766
| +87% | +$82.7M | 0.03% | 470 |
|
|
2020
Q2 | $27.3M | Sell |
287,104
-20,383
| -7% | -$1.79M | ﹤0.01% | 1425 |
|
|
2020
Q1 | $22M | Sell |
307,487
-17,469
| -5% | -$1.17M | ﹤0.01% | 1364 |
|
|
2019
Q4 | $22.4M | Sell |
324,956
-32,486
| -9% | -$2.41M | ﹤0.01% | 1552 |
|
|
2019
Q3 | $28.7M | Sell |
357,442
-47,655
| -12% | -$3.15M | ﹤0.01% | 1431 |
|
|
2019
Q2 | $26.1M | Buy |
405,097
+113,990
| +39% | +$10.8M | ﹤0.01% | 1516 |
|
|
2019
Q1 | $40M | Sell |
291,107
-15,312
| -5% | -$1.87M | ﹤0.01% | 1303 |
|
|
2018
Q4 | $27.7M | Buy |
306,419
+452
| +0.1% | +$63.3K | ﹤0.01% | 1424 |
|
|
2018
Q3 | $46.4M | Buy |
305,967
+1,187
| +0.4% | +$192K | 0.01% | 1307 |
|
|
2018
Q2 | $52.4M | Buy |
304,780
+32
| +0% | +$5.23K | 0.01% | 1257 |
|
|
2018
Q1 | $44.7M | Buy |
304,748
+887
| +0.3% | +$170K | 0.01% | 1348 |
|
|
2017
Q4 | $61.6M | Buy |
303,861
+131
| +0% | +$26.9K | 0.01% | 1200 |
|
|
2017
Q3 | $97.4M | Buy |
303,730
+915
| +0.3% | +$250K | 0.01% | 985 |
|
|
2017
Q2 | $68.4M | Buy |
302,815
+169
| +0.1% | +$34.7K | 0.01% | 1148 |
|
|
2017
Q1 | $68.2M | Buy |
302,646
+93
| +0% | +$18.9K | 0.01% | 1149 |
|
|
2016
Q4 | $59.9M | Buy |
302,553
+609
| +0.2% | +$133K | 0.01% | 1214 |
|
|
2016
Q3 | $74.2M | Buy |
301,944
+5,545
| +2% | +$1.95M | 0.01% | 1122 |
|
|
2016
Q2 | $172M | Buy |
296,399
+2,496
| +0.8% | +$1.46M | 0.02% | 735 |
|
|
2016
Q1 | $156M | Buy |
293,903
+985
| +0.3% | +$514K | 0.02% | 771 |
|
|
2015
Q4 | $206M | Buy |
292,918
+691
| +0.2% | +$454K | 0.03% | 644 |
|
|
2015
Q3 | $173M | Buy |
292,227
+30,304
| +12% | +$24.7M | 0.02% | 701 |
|
|
2015
Q2 | $217M | Buy |
+261,923
| New | +$229M | 0.03% | 656 |
|
Other funds holding MCRB
FP
VCM
VFT
Fidelity Investments's MCRB Position: Q1 2026 in Review
Fidelity Investments increased its Seres Therapeutics (MCRB) stake by 0.69% in Q1 2026, buying an estimated $141 and bringing the position to 1,752 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4615.
Fidelity Investments first reported a position in MCRB in Q2 2015 and has held it in 44 quarters since. The position peaked at $308M in Q2 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- Fidelity Investments held 1,752 shares of Seres Therapeutics worth $15.5K as of Q1 2026.
- Fidelity Investments bought 12 Seres Therapeutics shares in Q1 2026, an estimated $141.
- Seres Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4615 holding.
- Fidelity Investments first reported a position in Seres Therapeutics in Q2 2015 and has held it in 44 quarters since.
- Fidelity Investments's Seres Therapeutics position peaked at $308M in Q2 2021.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.